Global Consensus on Interstitial Cystitis/Bladder Pain Syndrome: An Update on Therapeutic Treatments
Neurourology and Urodynamics · 2026-01 · 45 (1) · 46-53
DOI: 10.1002/nau.70106 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Neurourology and Urodynamics, online erschienen am 10.08.2025. Verfasst von Karis Buford und 7 weiteren Autor:innen. Beteiligte Einrichtung: Corewell Health William Beaumont University Hospital, Royal Oak, Michigan, USA. Hauptthemen laut MEDLINE: Cystitis, Interstitial. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: The authors received no specific funding for this work..
Abstract (Originalsprache)
Aims
Interstitial cystitis/bladder pain syndrome (IC/BPS) is a chronic condition marked by chronic pain and voiding dysfunction, often without a clear cause. Management of which often requires a multidisciplinary approach, as well as multiple therapeutic interventions.
Methods
This review characterizes mechanisms and limitations of currently available treatment modalities for IC/BPS, as well as novel and investigational therapies.
Results
Conservative and supportive therapies include cognitive therapies, dietary and fluid management, pelvic floor exercises and bladder training. Additionally, pelvic floor directed therapies such as physical therapy, injections and nerve blocks should be considered. Cystoscopy with hydrodistension is both a diagnostic and therapeutic intervention. Currently available oral therapies include: pentosan polysulfate, amitriptyline, hydroxyzine, silodosin, and non‐opioid medications such as cyclobenzaprine. Immunotherapies include cyclosporine and tacrolimus. Available intravesical therapies include dimethyl sulfoxide, lidocaine, oxybutynin, and glycosaminoglycan substitution treatment. Neuromodulation is also available including sacral and pudendal neuromodulation. Finally, we explore emerging therapies and drug delivery systems.
Conclusions
In this review, we present currently available treatment options for IC/BPS. These include conservative therapies, oral medications, intravesical therapies, and neuromodulation. Novel and investigational therapies are presented as well as promise for future directions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Corewell Health William Beaumont University Hospital, Royal Oak, Michigan, USA.
- Oakland University William Beaumont School of Medicine, Rochester, Michigan, USA.
- Landesklinikum Baden-Mödling, Medical University Vienna, Vienna, Austria.
- CHARUSAT Hospital, Charotar University of Science and Technology, Anand, India.
- Emeritus University, Antwerp, Belgium.
- RMC Clinics, Budapest, Hungary.
ORCID-Profile: Karis Buford, Kenneth M Peters, Claus Riedl, Nagendra Nath Mishra, Wyndaele Jean Jacques, Sándor Lovász, Rui Almeida Pinto, Lori Birder
Förderung
- The authors received no specific funding for this work.
Zitieren
APA
Buford, K., Peters, K. M., Riedl, C., Mishra, N. N., Jacques, W. J., Lovász, S., Pinto, R. A., & Birder, L. (2026). Global Consensus on Interstitial Cystitis/Bladder Pain Syndrome: An Update on Therapeutic Treatments. Neurourology and Urodynamics, 45(1), 46-53. https://doi.org/10.1002/nau.70106
Vancouver
Buford K, Peters KM, Riedl C, Mishra NN, Jacques WJ, Lovász S, et al. Global Consensus on Interstitial Cystitis/Bladder Pain Syndrome: An Update on Therapeutic Treatments. Neurourology and Urodynamics. 2026;45(1):46-53. doi:10.1002/nau.70106
BibTeX
@article{Buford2026,
author = {Buford, Karis and Peters, Kenneth M and Riedl, Claus and Mishra, Nagendra Nath and Jacques, Wyndaele Jean and Lovász, Sándor and Pinto, Rui Almeida and Birder, Lori},
title = {Global Consensus on Interstitial Cystitis/Bladder Pain Syndrome: An Update on Therapeutic Treatments},
journal = {Neurourology and Urodynamics},
year = {2026},
volume = {45},
number = {1},
pages = {46--53},
doi = {10.1002/nau.70106}
}
EUVIMED